363 related articles for article (PubMed ID: 23937612)
21. Strategies to make protein serine/threonine (PP1, calcineurin) and tyrosine phosphatases (PTP1B) druggable: achieving specificity by targeting substrate and regulatory protein interaction sites.
Peti W; Page R
Bioorg Med Chem; 2015 Jun; 23(12):2781-5. PubMed ID: 25771485
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of the protein serine/threonine phosphatases.
Barford D
Trends Biochem Sci; 1996 Nov; 21(11):407-12. PubMed ID: 8987393
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).
Swingle MR; Honkanen RE
Assay Drug Dev Technol; 2014 Oct; 12(8):481-96. PubMed ID: 25383722
[TBL] [Abstract][Full Text] [Related]
24. Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors.
Kamada R; Kudoh F; Ito S; Tani I; Janairo JIB; Omichinski JG; Sakaguchi K
Pharmacol Ther; 2020 Nov; 215():107622. PubMed ID: 32650009
[TBL] [Abstract][Full Text] [Related]
25. Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor.
Dounay AB; Forsyth CJ
Curr Med Chem; 2002 Nov; 9(22):1939-80. PubMed ID: 12369865
[TBL] [Abstract][Full Text] [Related]
26. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents.
Sakoff JA; McCluskey A
Curr Pharm Des; 2004; 10(10):1139-59. PubMed ID: 15078146
[TBL] [Abstract][Full Text] [Related]
27. Discovery of protein kinase phosphatase inhibitors.
Vogt A; Lazo JS
Methods Mol Biol; 2007; 356():389-400. PubMed ID: 16988418
[TBL] [Abstract][Full Text] [Related]
28. Targeting protein serine/threonine phosphatases for drug development.
McConnell JL; Wadzinski BE
Mol Pharmacol; 2009 Jun; 75(6):1249-61. PubMed ID: 19299564
[TBL] [Abstract][Full Text] [Related]
29. Structure-based drug design of new leads for phosphatase research.
Combs AP
IDrugs; 2007 Feb; 10(2):112-5. PubMed ID: 17285463
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore identification: the case of the ser/thr protein phosphatase inhibitors.
Colby DA; Chamberlin AR
Mini Rev Med Chem; 2006 Jun; 6(6):657-65. PubMed ID: 16787376
[TBL] [Abstract][Full Text] [Related]
31. Serine/threonine protein phosphatases in apoptosis.
Klumpp S; Krieglstein J
Curr Opin Pharmacol; 2002 Aug; 2(4):458-62. PubMed ID: 12127881
[TBL] [Abstract][Full Text] [Related]
32. Roles and regulation of serine/threonine-specific protein phosphatases in the cell cycle.
Berndt N
Prog Cell Cycle Res; 2003; 5():497-510. PubMed ID: 14593745
[TBL] [Abstract][Full Text] [Related]
33. The phosphoprotein phosphatase family of Ser/Thr phosphatases as principal targets of naturally occurring toxins.
Pereira SR; Vasconcelos VM; Antunes A
Crit Rev Toxicol; 2011 Feb; 41(2):83-110. PubMed ID: 21288162
[TBL] [Abstract][Full Text] [Related]
34. Homology modeling and virtual screening approaches to identify potent inhibitors of slingshot phosphatase 1.
Park H; Park SY; Ryu SE
J Mol Graph Model; 2013 Feb; 39():65-70. PubMed ID: 23220283
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors.
Wipf P; Cunningham A; Rice RL; Lazo JS
Bioorg Med Chem; 1997 Jan; 5(1):165-77. PubMed ID: 9043668
[TBL] [Abstract][Full Text] [Related]
36. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis.
Nören-Müller A; Reis-Corrêa I; Prinz H; Rosenbaum C; Saxena K; Schwalbe HJ; Vestweber D; Cagna G; Schunk S; Schwarz O; Schiewe H; Waldmann H
Proc Natl Acad Sci U S A; 2006 Jul; 103(28):10606-11. PubMed ID: 16809424
[TBL] [Abstract][Full Text] [Related]
37. Plasmodium falciparum serine/threonine phoshoprotein phosphatases (PPP): from housekeeper to the 'holy grail'.
Bajsa J; Duke SO; Tekwani BL
Curr Drug Targets; 2008 Nov; 9(11):997-1012. PubMed ID: 18991611
[TBL] [Abstract][Full Text] [Related]
38. Docking interactions in protein kinase and phosphatase networks.
Reményi A; Good MC; Lim WA
Curr Opin Struct Biol; 2006 Dec; 16(6):676-85. PubMed ID: 17079133
[TBL] [Abstract][Full Text] [Related]
39. Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.
Chattopadhyay D; Swingle MR; Salter EA; Wood E; D'Arcy B; Zivanov C; Abney K; Musiyenko A; Rusin SF; Kettenbach A; Yet L; Schroeder CE; Golden JE; Dunham WH; Gingras AC; Banerjee S; Forbes D; Wierzbicki A; Honkanen RE
Biochem Pharmacol; 2016 Jun; 109():14-26. PubMed ID: 27002182
[TBL] [Abstract][Full Text] [Related]
40. Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential.
Wehenkel A; Bellinzoni M; Graña M; Duran R; Villarino A; Fernandez P; Andre-Leroux G; England P; Takiff H; Cerveñansky C; Cole ST; Alzari PM
Biochim Biophys Acta; 2008 Jan; 1784(1):193-202. PubMed ID: 17869195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
